LEO Pharma announces changes to its Global Leadership Team

Rhea-AI Summary

LEO Pharma appoints Nathalie Daste as new EVP, Global People and Corporate Affairs, effective October 1, 2023.

BALLERUP, Denmark--(BUSINESS WIRE)-- Today, LEO Pharma announced the appointment of Nathalie Daste as new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023.

Nathalie Daste brings extensive experience in organization design, transformation and capability building in the healthcare sector. Over the past decade, she has led a number of large-scale initiatives focused on building a distinctive culture and driving organizational performance for large companies in the pharma and industrial sectors. Nathalie has a proven track record at a global level at Novartis and McKinsey & Company where she started her career. She was recently Chief People Officer, Global Head Strategy & Commercial Excellence at CENTOGENE (NASDAQ:CTNG).

In her new role, Nathalie Daste will head LEO Pharma’s Global People function as well as Corporate Affairs, including sustainability and ESG. She succeeds Dennis Schmidt Pedersen, who has decided to step down from his role and leave LEO Pharma after six years in the company.

Nathalie Daste holds an MBA from INSEAD, France, and a master’s degree in management from ESSEC, France. She is French and will be relocating to Denmark with her family.

Christophe Bourdon, CEO of LEO Pharma, commented:

“I am looking very much forward to welcoming Nathalie Daste to the LEO Pharma family. Her vast experience from global life-science makes her a catch for LEO Pharma as we have been looking for a successor to Dennis Schmidt Pedersen. Nathalie brings a strong external view and experience from developing and leading people to LEO Pharma. With her joining the Global Leadership team, we can ensure these insights are brought into strategy. I would like to thank Dennis for everything he has done for LEO Pharma. We are in a good place today because of him. I wish him all the best of success in his next endeavour.”

Nathalie Daste said:

“I am truly excited to be joining LEO Pharma and becoming part of the amazing journey the company is on, helping people suffering from skin diseases. Having spent much time in Denmark with my family, I have experienced the Danish way of life and culture at close hand, and I look very much forward to relocating here and becoming part of it.”

Dennis Schmidt Pedersen commented:

“During my six years with LEO Pharma, my team and I together took a decentralized HR delivery model and globalized it in a highly effective process. I am leaving a very skilled and high-performing Global People organization fully aligned with LEO Pharma’s strategy. I am confident that the global team will continue to solidify the model. After shaping and executing a significant transformation in the people space, I have now decided to start a new chapter in my work-life outside LEO Pharma. I want to thank my amazing team for all the great moments we have shared.”

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,600 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230828609120/en/

Henrik Heskjær

+45 3140 6180

hdtdk@leo-pharma.com

Source: LEO Pharma